Anti-Human CTLA-4 Reference Antibody (JMW-3B3, RUO) (HB651226)

Name: Anti-Human CTLA-4 Reference Antibody (JMW-3B3, RUO)
Brand: abinScience
SKU: HB651226
Price: 370 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HB651226
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG
ID de clone	JMW-3B3
Activité biologique	Biotinylated JMW-3B3 (10 ug/mL) specifically detects sCTLA-4 in PBMC cell culture supernatants, and reveals no population-level difference in sCTLA-4 production between SLE patient and healthy donor PBMC stimulated with lupus-associated autoantigenic peptides [1]. JMW-3B3 (10 ug/mL; 5 days) blocks sCTLA-4 activity in PBMC from both healthy donors and SLE patients, with effects that vary by stimulant: it suppresses some pro-inflammatory and proliferative responses in healthy donors, while enhancing IL-10 production (and altering proliferation/cytokine profiles) in SLE patient PBMC, accentuating the inherent cytokine response differences between the two groups [1]. JMW-3B3 (20 ug/mL; overnight at 4°C) selectively binds intracellular sCTLA-4 in G-361 human malignant melanoma epithelial cells, but does not detect sCTLA-4 in A-375 human malignant melanoma epithelial cells [2]. JMW-3B3 (10 ug/mL; 5 days) enhances IFN-γ production from melanoma patient PBMC stimulated with a low dose (0.02 ug/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment [2]. JMW-3B3 (10 ug/mL; 5 days) enhances IL-17A production from healthy donor PBMC stimulated with a high dose (1 ug/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment [2].
Cible	CD152, CTLA-4, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P16410
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	JMW-3B3, JMW3B3, JMW3B3
Contexte	Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy). 1. Schwartz, JC. et al. (2001) Nature 410, 604-8. PMID: 11279501 2. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502 3. Teft, WA. et al. (2006) Annual review of immunology 24, 65-97. PMID: 16551244 4. Linsley, PS. et al. (1991) The Journal of experimental medicine 174, 561-9. PMID: 1714933 5. Zheng, Y. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 1683-91. PMID: 18641304 6. Ramagopal, UA. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E4223-E4232. PMID: 28484017
Reférences	1. Dahal LN, et al. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther. 2016;18:180. Published 2016 Aug 4. [HB651226] 2. Khanolkar RC, et al. TGFβ2 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. Front Immunol. 2022;12:763877. Published 2022 Jan 5. [HB651226]
Note	For research use only. Not suitable for clinical or therapeutic use.